$REGN (Regeneron Pharmaceuticals, Inc.) — investor discussion on X

Five-factor rating: Buy (sector percentile 80.4%)

Graded daily on value B, growth B+, profitability A-, momentum B, revisions B+. Sector-relative, identical for every user.

Most active credible voices on $REGN

@nataninvesting (Natan) — 51 mentions · 38.7K followers
@mathlonning (Matheus Lonning) — 12 mentions · 4.7K followers
@stockmktnewz (Evan) — 10 mentions · 1.2M followers

Recent headlines featuring $REGN

2026-10-30: Sanofi lifts 2026 outlook again as Dupixent quarterly sales reach €5.69bn
2026-10-01: Sanofi and Regeneron expand alliance in deal worth up to $8 billion

Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $REGN are available with SpikePanel Pro.

Stock Ratings · Today Headlines · SpikePanel

For richer charts and full features, open SpikePanel on desktop.

$REGN — what investors on X are saying · SpikePanel

$REGNRegeneron Pharmaceuticals, Inc. · Biotechnology · $99.0B

$973.34

+1.3%

Event thread

Key events, in time order

25 items

2026-10-30 → 11-03EarningsBull🔥Developing
Regeneron Gets Analyst Target Hikes After Q3 Beat
Multiple analysts raise targets; stock hits 52-week high
D1 +13.3% · since +3.6%
3 waves of this story
- 2026-10-30 Revenue of $5.1B and adj. EPS of $20.07 beat estimates, driven by Dupixent and Eylea HD growth.
- 2026-10-31 Dupixent global quarterly sales $6.5B, total revenue +36% YoY; stock hits 52-week high
- 2026-11-03 Multiple analysts raise targets; stock hits 52-week high
2026-10-30Earnings
Earnings report
D1 +13.3% · since +3.6%

23 earlier events

2026-10-308-K filing
8-K: Item 2.02, Item 9.01
D1 +13.3% · since +3.6%
2026-10-26CompanyBull
Regeneron Expands BARDA Ebola Drug Supply Deal
Adds ~$270M supply contract, boosting U.S. preparedness stockpile
D1 +0.3% · +5d +19.0%
2026-10-18Capital
Regeneron CSO Sells $3.2M in Stock
Insider Andrew Murphy sold 4,147 shares on Oct 14 under plan, priced $753.76-$781.47
D1 -1.1% · +5d +3.3%
2026-10-15Analyst
UBS upgrades to Buy
D1 +2.3% · +5d +2.9%
2026-10-12ProductBull
Regeneron Reports Positive 84-Week Pasatru Data
Phase 3 OPTIMA shows sustained efficacy in halting rogue bone growth
D1 +2.2% · +5d +2.5%
2026-10-06ProductBull
Regeneron Presents Late-Breaking Libtayo Survival Data at ESMO 2026
Phase 3 C-POST longer-term survival supports adjuvant CSCC treatment
D1 +1.7% · +5d +1.9%
2026-10-01 → 10-06CompanyBull
Sanofi $1.0B Upfront Deepens Regeneron Pact
Sixth amendment brings $1.0B upfront, strengthening long-term alliance
D1 -3.1% · +5d +0.6%
2 waves of this story
- 2026-10-01 Expanded collaboration on next-gen long-acting immunology antibodies
- 2026-10-06 Sixth amendment brings $1.0B upfront, strengthening long-term alliance
2026-10-068-K filing
8-K: Item 1.01, Item 2.02, Item 8.01
D1 +1.7% · +5d +1.9%
2026-10-018-K filing
8-K: Item 5.02, Item 9.01
D1 -3.1% · +5d +0.6%
2026-10-01Analyst
Argus Research upgrades to Buy
D1 -3.1% · +5d +0.6%
2026-09-24Company
Regeneron updates pipeline & commercial momentum at Bernstein forum
Execs cite EYLEA HD momentum, Dupixent growth, late-stage pipeline amid biosimilar competition.
D1 -0.7% · +5d -7.7%
2026-09-14Company
Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts at Morgan Stanley Conference
Management updates on key product growth and pipeline catalysts at industry conference
D1 +1.6% · +5d +0.6%
2026-08-19Analyst
Leerink raises Regeneron PT to $824, keeps Market Perform
PT raised from $641, but rating unchanged, reflecting cautious optimism
D1 +3.8% · +5d -3.1%
2026-08-18CapitalBull
BlackRock builds new $5.68B stake in Regeneron
13F filing shows 9.11M shares acquired, signaling institutional inflow
D1 +0.5% · +5d +2.9%
2026-08-18ProductBear
Regeneron ends REGN7041 uveitis study on safety
Phase 1/2 trial for non-infectious uveitis terminated after unfavorable benefit-risk review, hitting pipeline
D1 +0.5% · +5d +2.9%
2026-07-30 → 08-06EarningsBull
Regeneron Q2 Beat, Dupixent & Eylea HD Drive Growth
Q2 revenue +17% YoY to $4.291B; Eylea HD US net sales +52%, Libtayo +30%; FDA/EMA accepted cemdisiran filing for gMG
D1 +6.2% · +5d +4.6%
4 waves of this story
- 2026-07-30 Q2 results beat on revenue and profit, driven by strong demand for Dupixent and high-dose Eylea.
- 2026-07-30 Q2 revenue $4.3B beat; Dupixent global sales +38%, Eylea HD US sales +52%
- 2026-08-05 Citigroup raises PT to $740 post-earnings, reflecting institutional confidence
- 2026-08-06 Q2 revenue +17% YoY to $4.291B; Eylea HD US net sales +52%, Libtayo +30%; FDA/EMA accepted cemdisiran filing for gMG
2026-07-18 → 08-05RegulationBear
Multiple Law Firms Announce Securities Class Action Lawsuits Against Regeneron
Multiple firms issued reminders with a lead plaintiff deadline of 9/14/2026, alleging statements about the Phase III Fianlimab-Libtayo study.
D1 -0.7% · +5d -0.7%
18 waves of this story
- 2026-07-18 At least four independent law firms have announced investigations or lawsuits alleging securities fraud, inviting investors to join.
- 2026-07-18 Multiple law firms issue reminders, including DJS, Schall, and Faruqi, with deadline on Sept 14, 2026.
- 2026-07-20 Two additional law firms (DJS Law Group, Schall Law Firm) issued reminders today, same line as prior event, no new facts.
- 2026-07-20 On July 20, 2026, multiple law firms including Bernstein Liebhard, DJS Law Group, Faruqi & Faruqi, Schall Law Firm, and Levi & Korsinsky issued investor alerts regarding a securities class action lawsuit against Regeneron for alleged securities law violations, with a lead plaintiff deadline set for September 14, 2026.
- 2026-07-22 Multiple firms confirm class action with Sept 14 deadline, allegations involve Fianlimab-Libtayo trial disclosures.
- 2026-07-23 Multiple law firms issue class action notices, adding Sept 14 lead plaintiff deadline and Phase 3 trial disclosure allegations
- 2026-07-24 Multiple law firms issue reminders with Sept 14 deadline, no new facts, just repetition.
- 2026-07-24 Multiple law firms issued notices today alleging trial misrepresentations, with September 14 deadline highlighted
- 2026-07-27 BFA, Bronstein, Faruqi among firms flagging Sept 14 lead plaintiff deadline after 9% stock drop triggered fraud suit
- 2026-07-28 Multiple law firms issue class action reminders, alleging misleading statements on Fianlimab-L Phase III trial; stock fell nearly 10%
- 2026-07-29 Multiple firms issued reminders today, alleging misleading disclosures on Fianlimab-Libtayo trial, stock fell nearly 10%
- 2026-07-29 Multiple law firms issue reminders over class action alleging statements on Fianlimab-Libtayo trial, deadline Sept 14.
- 2026-07-31 BFA, Bronstein, Pomerantz remind investors of class action deadlines
- 2026-08-01 Multiple law firms issued reminders today, revealing details of key trial failure, escalating the litigation.
- 2026-08-01 BofA's stake increase coincides with lawsuit deadline, ongoing litigation risk
- 2026-08-04 Multiple law firms file class actions over trial disclosures, stock drops nearly 10%
- 2026-08-04 Multiple firms issued reminders today; lawsuit relates to Fianlimab-L trial failure and stock drop, deadline Sept 14.
- 2026-08-05 Multiple firms issued reminders with a lead plaintiff deadline of 9/14/2026, alleging statements about the Phase III Fianlimab-Libtayo study.
2026-08-05Analyst
Analysts Raise Regeneron PT & Upgrade
Citi raises PT to $740 (Neutral); Wall Street Zen upgrades to Buy; reflects cautious optimism on Eylea HD & pipeline
D1 +1.0% · +5d +3.8%
2026-08-03ProductBear
Biocon Launches Yesafili, a Biosimilar to Regeneron's Eylea 2 mg
Biocon commercially launches Yesafili in the U.S., directly competing with Regeneron's Eylea for ophthalmology conditions
D1 -0.4% · +5d +6.4%
2026-07-21 → 08-03CapitalBull
Multiple Institutions Increase Regeneron Holdings
At least 4 law firms file class action alleging securities fraud over trial misrepresentations; lead plaintiff deadline 9/14/2026
D1 +0.5% · +5d +3.0%
2 waves of this story
- 2026-07-21 AlTi Global raises 312.7%, Baader Bank 138.7%, Assetmark 9.2%.
- 2026-08-03 At least 4 law firms file class action alleging securities fraud over trial misrepresentations; lead plaintiff deadline 9/14/2026
2026-08-03ProductBear
Biocon Launches Eylea Biosimilar Yesafili in the US
Biocon announces US launch of Yesafili, competing with Regeneron's Eylea
D1 -0.4% · +5d +6.4%
2026-07-308-K filing
8-K: Item 2.02, Item 9.01
D1 +6.2% · +5d +4.6%
2026-07-30Earnings
Earnings report
2026年第二季度总收入同比增长17%至43亿美元，非GAAP每股收益增长11%至14.29美元。
D1 +6.2% · +5d +4.6%

①

Bull vs bear

by direction · sourced

Bull signals0

None yet

Bear signals0

None yet

Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice

⑩

Discussion

be the first

Be civil · your views are your own

No comments yet.

Facts and opinions separated · All items sourced · Not investment advice

Event thread

Key events, in time order

25 items

2026-10-30 → 11-03EarningsBull🔥Developing
Regeneron Gets Analyst Target Hikes After Q3 Beat
Multiple analysts raise targets; stock hits 52-week high
D1 +13.3% · since +3.6%
3 waves of this story
- 2026-10-30 Revenue of $5.1B and adj. EPS of $20.07 beat estimates, driven by Dupixent and Eylea HD growth.
- 2026-10-31 Dupixent global quarterly sales $6.5B, total revenue +36% YoY; stock hits 52-week high
- 2026-11-03 Multiple analysts raise targets; stock hits 52-week high
2026-10-30Earnings
Earnings report
D1 +13.3% · since +3.6%
2026-10-308-K filing
8-K: Item 2.02, Item 9.01
D1 +13.3% · since +3.6%
2026-10-26CompanyBull
Regeneron Expands BARDA Ebola Drug Supply Deal
Adds ~$270M supply contract, boosting U.S. preparedness stockpile
D1 +0.3% · +5d +19.0%
2026-10-18Capital
Regeneron CSO Sells $3.2M in Stock
Insider Andrew Murphy sold 4,147 shares on Oct 14 under plan, priced $753.76-$781.47
D1 -1.1% · +5d +3.3%

20 earlier events

2026-10-15Analyst
UBS upgrades to Buy
D1 +2.3% · +5d +2.9%
2026-10-12ProductBull
Regeneron Reports Positive 84-Week Pasatru Data
Phase 3 OPTIMA shows sustained efficacy in halting rogue bone growth
D1 +2.2% · +5d +2.5%
2026-10-06ProductBull
Regeneron Presents Late-Breaking Libtayo Survival Data at ESMO 2026
Phase 3 C-POST longer-term survival supports adjuvant CSCC treatment
D1 +1.7% · +5d +1.9%
2026-10-01 → 10-06CompanyBull
Sanofi $1.0B Upfront Deepens Regeneron Pact
Sixth amendment brings $1.0B upfront, strengthening long-term alliance
D1 -3.1% · +5d +0.6%
2 waves of this story
- 2026-10-01 Expanded collaboration on next-gen long-acting immunology antibodies
- 2026-10-06 Sixth amendment brings $1.0B upfront, strengthening long-term alliance
2026-10-068-K filing
8-K: Item 1.01, Item 2.02, Item 8.01
D1 +1.7% · +5d +1.9%
2026-10-018-K filing
8-K: Item 5.02, Item 9.01
D1 -3.1% · +5d +0.6%
2026-10-01Analyst
Argus Research upgrades to Buy
D1 -3.1% · +5d +0.6%
2026-09-24Company
Regeneron updates pipeline & commercial momentum at Bernstein forum
Execs cite EYLEA HD momentum, Dupixent growth, late-stage pipeline amid biosimilar competition.
D1 -0.7% · +5d -7.7%
2026-09-14Company
Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts at Morgan Stanley Conference
Management updates on key product growth and pipeline catalysts at industry conference
D1 +1.6% · +5d +0.6%
2026-08-19Analyst
Leerink raises Regeneron PT to $824, keeps Market Perform
PT raised from $641, but rating unchanged, reflecting cautious optimism
D1 +3.8% · +5d -3.1%
2026-08-18CapitalBull
BlackRock builds new $5.68B stake in Regeneron
13F filing shows 9.11M shares acquired, signaling institutional inflow
D1 +0.5% · +5d +2.9%
2026-08-18ProductBear
Regeneron ends REGN7041 uveitis study on safety
Phase 1/2 trial for non-infectious uveitis terminated after unfavorable benefit-risk review, hitting pipeline
D1 +0.5% · +5d +2.9%
2026-07-30 → 08-06EarningsBull
Regeneron Q2 Beat, Dupixent & Eylea HD Drive Growth
Q2 revenue +17% YoY to $4.291B; Eylea HD US net sales +52%, Libtayo +30%; FDA/EMA accepted cemdisiran filing for gMG
D1 +6.2% · +5d +4.6%
4 waves of this story
- 2026-07-30 Q2 results beat on revenue and profit, driven by strong demand for Dupixent and high-dose Eylea.
- 2026-07-30 Q2 revenue $4.3B beat; Dupixent global sales +38%, Eylea HD US sales +52%
- 2026-08-05 Citigroup raises PT to $740 post-earnings, reflecting institutional confidence
- 2026-08-06 Q2 revenue +17% YoY to $4.291B; Eylea HD US net sales +52%, Libtayo +30%; FDA/EMA accepted cemdisiran filing for gMG
2026-07-18 → 08-05RegulationBear
Multiple Law Firms Announce Securities Class Action Lawsuits Against Regeneron
Multiple firms issued reminders with a lead plaintiff deadline of 9/14/2026, alleging statements about the Phase III Fianlimab-Libtayo study.
D1 -0.7% · +5d -0.7%
18 waves of this story
- 2026-07-18 At least four independent law firms have announced investigations or lawsuits alleging securities fraud, inviting investors to join.
- 2026-07-18 Multiple law firms issue reminders, including DJS, Schall, and Faruqi, with deadline on Sept 14, 2026.
- 2026-07-20 Two additional law firms (DJS Law Group, Schall Law Firm) issued reminders today, same line as prior event, no new facts.
- 2026-07-20 On July 20, 2026, multiple law firms including Bernstein Liebhard, DJS Law Group, Faruqi & Faruqi, Schall Law Firm, and Levi & Korsinsky issued investor alerts regarding a securities class action lawsuit against Regeneron for alleged securities law violations, with a lead plaintiff deadline set for September 14, 2026.
- 2026-07-22 Multiple firms confirm class action with Sept 14 deadline, allegations involve Fianlimab-Libtayo trial disclosures.
- 2026-07-23 Multiple law firms issue class action notices, adding Sept 14 lead plaintiff deadline and Phase 3 trial disclosure allegations
- 2026-07-24 Multiple law firms issue reminders with Sept 14 deadline, no new facts, just repetition.
- 2026-07-24 Multiple law firms issued notices today alleging trial misrepresentations, with September 14 deadline highlighted
- 2026-07-27 BFA, Bronstein, Faruqi among firms flagging Sept 14 lead plaintiff deadline after 9% stock drop triggered fraud suit
- 2026-07-28 Multiple law firms issue class action reminders, alleging misleading statements on Fianlimab-L Phase III trial; stock fell nearly 10%
- 2026-07-29 Multiple firms issued reminders today, alleging misleading disclosures on Fianlimab-Libtayo trial, stock fell nearly 10%
- 2026-07-29 Multiple law firms issue reminders over class action alleging statements on Fianlimab-Libtayo trial, deadline Sept 14.
- 2026-07-31 BFA, Bronstein, Pomerantz remind investors of class action deadlines
- 2026-08-01 Multiple law firms issued reminders today, revealing details of key trial failure, escalating the litigation.
- 2026-08-01 BofA's stake increase coincides with lawsuit deadline, ongoing litigation risk
- 2026-08-04 Multiple law firms file class actions over trial disclosures, stock drops nearly 10%
- 2026-08-04 Multiple firms issued reminders today; lawsuit relates to Fianlimab-L trial failure and stock drop, deadline Sept 14.
- 2026-08-05 Multiple firms issued reminders with a lead plaintiff deadline of 9/14/2026, alleging statements about the Phase III Fianlimab-Libtayo study.
2026-08-05Analyst
Analysts Raise Regeneron PT & Upgrade
Citi raises PT to $740 (Neutral); Wall Street Zen upgrades to Buy; reflects cautious optimism on Eylea HD & pipeline
D1 +1.0% · +5d +3.8%
2026-08-03ProductBear
Biocon Launches Yesafili, a Biosimilar to Regeneron's Eylea 2 mg
Biocon commercially launches Yesafili in the U.S., directly competing with Regeneron's Eylea for ophthalmology conditions
D1 -0.4% · +5d +6.4%
2026-07-21 → 08-03CapitalBull
Multiple Institutions Increase Regeneron Holdings
At least 4 law firms file class action alleging securities fraud over trial misrepresentations; lead plaintiff deadline 9/14/2026
D1 +0.5% · +5d +3.0%
2 waves of this story
- 2026-07-21 AlTi Global raises 312.7%, Baader Bank 138.7%, Assetmark 9.2%.
- 2026-08-03 At least 4 law firms file class action alleging securities fraud over trial misrepresentations; lead plaintiff deadline 9/14/2026
2026-08-03ProductBear
Biocon Launches Eylea Biosimilar Yesafili in the US
Biocon announces US launch of Yesafili, competing with Regeneron's Eylea
D1 -0.4% · +5d +6.4%
2026-07-308-K filing
8-K: Item 2.02, Item 9.01
D1 +6.2% · +5d +4.6%
2026-07-30Earnings
Earnings report
2026年第二季度总收入同比增长17%至43亿美元，非GAAP每股收益增长11%至14.29美元。
D1 +6.2% · +5d +4.6%

$REGN (Regeneron Pharmaceuticals, Inc.) — investor discussion on X

Five-factor rating: Buy (sector percentile 80.4%)

Most active credible voices on $REGN

Recent headlines featuring $REGN

$REGN (Regeneron Pharmaceuticals, Inc.) — investor discussion on X

Five-factor rating: Buy (sector percentile 80.4%)

Most active credible voices on $REGN

Recent headlines featuring $REGN

Regeneron Gets Analyst Target Hikes After Q3 Beat

Earnings report

8-K: Item 2.02, Item 9.01

Regeneron Expands BARDA Ebola Drug Supply Deal

Regeneron CSO Sells $3.2M in Stock

UBS upgrades to Buy

Regeneron Reports Positive 84-Week Pasatru Data

Regeneron Presents Late-Breaking Libtayo Survival Data at ESMO 2026

Sanofi $1.0B Upfront Deepens Regeneron Pact

8-K: Item 1.01, Item 2.02, Item 8.01

8-K: Item 5.02, Item 9.01

Argus Research upgrades to Buy

Regeneron updates pipeline & commercial momentum at Bernstein forum

Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts at Morgan Stanley Conference

Leerink raises Regeneron PT to $824, keeps Market Perform

BlackRock builds new $5.68B stake in Regeneron

Regeneron ends REGN7041 uveitis study on safety

Regeneron Q2 Beat, Dupixent & Eylea HD Drive Growth

Multiple Law Firms Announce Securities Class Action Lawsuits Against Regeneron

Analysts Raise Regeneron PT & Upgrade

Biocon Launches Yesafili, a Biosimilar to Regeneron's Eylea 2 mg

Multiple Institutions Increase Regeneron Holdings

Biocon Launches Eylea Biosimilar Yesafili in the US

8-K: Item 2.02, Item 9.01

Earnings report

Bull vs bear

Discussion

Regeneron Gets Analyst Target Hikes After Q3 Beat

Earnings report

8-K: Item 2.02, Item 9.01

Regeneron Expands BARDA Ebola Drug Supply Deal

Regeneron CSO Sells $3.2M in Stock

UBS upgrades to Buy

Regeneron Reports Positive 84-Week Pasatru Data

Regeneron Presents Late-Breaking Libtayo Survival Data at ESMO 2026

Sanofi $1.0B Upfront Deepens Regeneron Pact

8-K: Item 1.01, Item 2.02, Item 8.01

8-K: Item 5.02, Item 9.01

Argus Research upgrades to Buy

Regeneron updates pipeline & commercial momentum at Bernstein forum

Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts at Morgan Stanley Conference

Leerink raises Regeneron PT to $824, keeps Market Perform

BlackRock builds new $5.68B stake in Regeneron

Regeneron ends REGN7041 uveitis study on safety

Regeneron Q2 Beat, Dupixent & Eylea HD Drive Growth

Multiple Law Firms Announce Securities Class Action Lawsuits Against Regeneron

Analysts Raise Regeneron PT & Upgrade

Biocon Launches Yesafili, a Biosimilar to Regeneron's Eylea 2 mg

Multiple Institutions Increase Regeneron Holdings

Biocon Launches Eylea Biosimilar Yesafili in the US

8-K: Item 2.02, Item 9.01

Earnings report